Nyxoah (NASDAQ:NYXH) Upgraded to “Hold” at Wall Street Zen

Posted by Francis Steltz on Aug 2nd, 2026

Wall Street Zen upgraded shares of Nyxoah (NASDAQ:NYXH – Free Report) to a hold rating in a report released on Saturday morning.

Several other research firms have also issued reports on NYXH. Stifel Nicolaus dropped their price objective on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Wednesday, June 17th. Weiss Ratings lowered shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $7.00 target price (down from $9.00) on shares of Nyxoah in a research report on Wednesday, May 13th. Finally, Robert W. Baird set a $2.85 target price on Nyxoah in a research note on Thursday, July 9th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nyxoah presently has a consensus rating of “Hold” and a consensus target price of $5.96.

Read Our Latest Analysis on NYXH

Nyxoah Stock Down 0.7%

Shares of NASDAQ:NYXH opened at $1.40 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.88 and a current ratio of 0.99. Nyxoah has a 1 year low of $1.26 and a 1 year high of $8.59. The stock has a market capitalization of $54.26 million, a P/E ratio of -0.56 and a beta of 1.61. The stock has a 50-day simple moving average of $1.80 and a 200-day simple moving average of $3.07.

Nyxoah (NASDAQ:NYXH – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.11. The firm had revenue of $7.38 million during the quarter, compared to the consensus estimate of $7.05 million. Nyxoah had a negative net margin of 543.21% and a negative return on equity of 163.73%. Equities analysts forecast that Nyxoah will post -1.67 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Heights Capital Management Inc. acquired a new stake in Nyxoah during the 4th quarter valued at approximately $3,575,000. Deutsche Bank AG raised its position in shares of Nyxoah by 40.0% in the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Nyxoah during the 3rd quarter valued at approximately $98,000. Bank of America Corp DE boosted its stake in shares of Nyxoah by 152.7% during the 3rd quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock valued at $91,000 after buying an additional 12,012 shares during the last quarter. Finally, Raymond James Financial Inc. grew its position in shares of Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after buying an additional 3,353 shares in the last quarter.

Nyxoah Company Profile

(Get Free Report)

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.